Multiple sclerosis (MS) is a chronic disease in which the immune system mistakenly attacks the protective coating around nerve fibers in the brain and spinal cord. This damage disrupts the electrical signals that travel between the brain and the rest of the body, causing a wide range of symptoms from vision problems to difficulty walking. An estimated 2.9 million people worldwide live with MS, and the number has been rising steadily over the past decade.
What Happens Inside the Nervous System
Nerve fibers are wrapped in a fatty insulating layer called myelin, which works much like the rubber coating on an electrical wire. Myelin allows signals to travel quickly and efficiently. In MS, certain immune cells that normally fight infections cross into the brain and spinal cord and begin destroying this insulation.
Two types of immune cells drive the damage. One group punches holes in the membranes of myelin-producing cells, triggering a chain reaction that kills them. Another group produces antibodies that further target the nerve coating. Over time, the exposed nerve fibers themselves can become injured. Where this damage occurs, scar tissue (lesions or “plaques”) forms. These plaques are the hallmark of the disease, and their location determines which symptoms a person experiences.
Early Symptoms and Warning Signs
MS symptoms vary enormously from person to person because lesions can appear almost anywhere in the brain or spinal cord. Vision problems are one of the most recognizable early signs. Inflammation of the optic nerve, called optic neuritis, is the first symptom in roughly 20% of people who are eventually diagnosed. It typically causes pain with eye movement and blurred or dimmed vision in one eye.
Other common early symptoms include numbness or tingling in the face, arms, or legs, muscle weakness, difficulty with balance or coordination, and unusual fatigue that doesn’t improve with rest. Some people notice electric-shock sensations running down the spine when they bend their neck. Bladder urgency and cognitive changes, like difficulty concentrating or finding words, can also appear early, though they’re easy to dismiss as stress or aging.
The Three Main Types
MS follows different patterns depending on the person, and doctors classify it into three main types based on how the disease behaves over time.
Relapsing-Remitting MS
About 85% of people are initially diagnosed with this form. It’s defined by distinct flare-ups (relapses) where new symptoms appear or existing ones worsen, followed by periods of partial or complete recovery (remissions). These quiet stretches can last months or years. However, nearly half of all relapses leave behind some lasting deficit, so disability can accumulate in a stair-step pattern even between obvious flare-ups.
Secondary Progressive MS
Most people with relapsing-remitting MS eventually transition to this phase if left untreated. The shift happens at a median of about 19 years after the initial diagnosis. Rather than distinct attacks and recoveries, disability worsens more steadily. Some people still experience occasional relapses on top of the gradual decline, while others simply notice a slow, continuous slide.
Primary Progressive MS
A smaller group, roughly 10 to 15% of people with MS, never experiences the relapse-remission cycle at all. Instead, neurological function worsens from the very beginning in a steady, gradual way. This type tends to be diagnosed later in life and often starts with progressive difficulty walking.
What Causes MS
No single cause has been identified, but a combination of genetic susceptibility and environmental triggers appears to set the disease in motion. The strongest environmental link discovered so far involves Epstein-Barr virus (EBV), the common virus that causes mono. More than 99% of people with MS have been infected with EBV, compared to about 90 to 95% of the general population. A landmark study found that EBV infection increases the risk of developing MS by 32-fold, with a typical gap of about five years between infection and diagnosis. People who experienced symptomatic mono have more than double the risk compared to those who caught the virus without noticeable illness.
Other established risk factors include low vitamin D levels (MS is more common the farther you live from the equator), smoking, obesity during adolescence, and having a close family member with the disease. Women are diagnosed two to three times more often than men.
How MS Is Diagnosed
There is no single blood test for MS. Diagnosis relies on showing that damage has occurred in at least two separate areas of the central nervous system at two different points in time, a principle doctors call “dissemination in space and time.” The main tools are MRI scans and, sometimes, a spinal tap.
MRI is the cornerstone. It can reveal lesions in the brain and spinal cord even when a person feels fine. Doctors look for new lesions appearing on follow-up scans as evidence that the disease is active. A spinal tap can detect specific antibody patterns in the spinal fluid that strongly support an MS diagnosis, and under the current diagnostic guidelines, finding these antibodies can sometimes substitute for the requirement to show damage at two different time points. This means some people can be diagnosed after a single clinical episode rather than waiting for a second attack.
Treatment and Disease Management
MS treatment has changed dramatically over the past two decades. More than a dozen disease-modifying therapies are now available, and they work through different strategies to reduce immune attacks on the nervous system.
Some therapies work by trapping immune cells in the lymph nodes so they can’t reach the brain. Others deplete specific populations of immune cells, particularly the antibody-producing B cells that play a key role in MS. Still others shift the overall immune response away from inflammation or block immune cells from crossing the blood-brain barrier into the central nervous system. These medications are taken as pills, self-injections, or periodic infusions, and they primarily aim to reduce the frequency and severity of relapses and slow the accumulation of new brain lesions.
Treatment decisions are highly individual. Milder therapies have fewer side effects but may be less potent, while more aggressive options carry greater risks but can be more effective at halting disease activity. Many neurologists now favor starting with a higher-efficacy therapy early, especially in younger patients or those with active disease on MRI, because preventing early damage appears to have long-term benefits for disability outcomes.
Beyond disease-modifying therapy, relapses themselves are often treated with short courses of high-dose steroids to reduce inflammation and speed recovery. Physical therapy, occupational therapy, and medications for specific symptoms like spasticity, pain, bladder dysfunction, and fatigue are also central to day-to-day management.
Living With MS: Prognosis and Life Expectancy
MS is a lifelong condition, but it is not a death sentence. A large population study tracking patients over 60 years found a median life expectancy of 74.7 years for people with MS, compared to 81.8 years in the general population, a gap of about seven years. That data reflects outcomes from an era when fewer treatments were available, so the gap may be narrowing for people diagnosed today with access to modern therapies.
The course of MS is notoriously unpredictable. Some people experience only a handful of mild relapses over decades and maintain near-normal function. Others accumulate disability more quickly. Factors associated with a better outlook include being diagnosed young, having relapsing-remitting disease, being female, and having few lesions on the initial MRI. Regular monitoring with MRI and neurological exams allows doctors to detect breakthrough disease activity early and switch treatments when needed.
MS in Children and Adolescents
Although MS is primarily diagnosed in adults between ages 20 and 50, it can begin in childhood. Onset before age 10 is rare, accounting for less than 1% of all cases, but adolescent onset is well recognized. Children with MS tend to relapse more frequently in the first few years compared to adults, though they also tend to recover more fully from individual attacks. Younger children are more likely to present with unusual features like altered mental status, vomiting, or seizures, which can make distinguishing MS from other childhood brain conditions particularly challenging. Seizures occur in 5 to 16% of pediatric MS cases, a rate higher than in adult-onset disease.